PortalPublikationenThiotepa-busulfan-fludarabine (TBF) conditioning regimen in ...

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

Standard

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. / Battipaglia, Giorgia; Mauff, Katya; Wendel, Lotus; Angelucci, Emanuele; Mohty, Mohamad; Arcese, William; Santarone, Stella; Rubio, Marie Therese; Kroger, Nicolaus; Fox, Maria Laura; Blaise, Didier; Iori, Anna Paola; Fanin, Renato; Chalandon, Yves; Pioltelli, Pietro; Marotta, Giuseppe; Chiusolo, Patrizia; Sever, Matjaz; Solano, Carlos; Contentin, Nathalie; de Wreede, Liesbeth C; Czerw, Tomasz; Hernandez-Boluda, Juan Carlos; Hayden, Patrick; McLornan, Donal; Yakoub-Agha, Ibrahim.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 7, 07.2021, S. 1593-1602.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Battipaglia, G, Mauff, K, Wendel, L, Angelucci, E, Mohty, M, Arcese, W, Santarone, S, Rubio, MT, Kroger, N, Fox, ML, Blaise, D, Iori, AP, Fanin, R, Chalandon, Y, Pioltelli, P, Marotta, G, Chiusolo, P, Sever, M, Solano, C, Contentin, N, de Wreede, LC, Czerw, T, Hernandez-Boluda, JC, Hayden, P, McLornan, D & Yakoub-Agha, I 2021, 'Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 56, Nr. 7, S. 1593-1602. https://doi.org/10.1038/s41409-021-01222-z

APA

Battipaglia, G., Mauff, K., Wendel, L., Angelucci, E., Mohty, M., Arcese, W., Santarone, S., Rubio, M. T., Kroger, N., Fox, M. L., Blaise, D., Iori, A. P., Fanin, R., Chalandon, Y., Pioltelli, P., Marotta, G., Chiusolo, P., Sever, M., Solano, C., ... Yakoub-Agha, I. (2021). Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 56(7), 1593-1602. https://doi.org/10.1038/s41409-021-01222-z

Vancouver

Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W et al. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2021 Jul;56(7):1593-1602. https://doi.org/10.1038/s41409-021-01222-z

Bibtex

@article{4a9977da4a37493291eec8cf1f3824b9,
title = "Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT",
abstract = "Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.",
keywords = "Busulfan, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Neoplasms, Primary Myelofibrosis, Retrospective Studies, Thiotepa, Transplantation Conditioning, Vidarabine/analogs & derivatives",
author = "Giorgia Battipaglia and Katya Mauff and Lotus Wendel and Emanuele Angelucci and Mohamad Mohty and William Arcese and Stella Santarone and Rubio, {Marie Therese} and Nicolaus Kroger and Fox, {Maria Laura} and Didier Blaise and Iori, {Anna Paola} and Renato Fanin and Yves Chalandon and Pietro Pioltelli and Giuseppe Marotta and Patrizia Chiusolo and Matjaz Sever and Carlos Solano and Nathalie Contentin and {de Wreede}, {Liesbeth C} and Tomasz Czerw and Hernandez-Boluda, {Juan Carlos} and Patrick Hayden and Donal McLornan and Ibrahim Yakoub-Agha",
year = "2021",
month = jul,
doi = "10.1038/s41409-021-01222-z",
language = "English",
volume = "56",
pages = "1593--1602",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

AU - Battipaglia, Giorgia

AU - Mauff, Katya

AU - Wendel, Lotus

AU - Angelucci, Emanuele

AU - Mohty, Mohamad

AU - Arcese, William

AU - Santarone, Stella

AU - Rubio, Marie Therese

AU - Kroger, Nicolaus

AU - Fox, Maria Laura

AU - Blaise, Didier

AU - Iori, Anna Paola

AU - Fanin, Renato

AU - Chalandon, Yves

AU - Pioltelli, Pietro

AU - Marotta, Giuseppe

AU - Chiusolo, Patrizia

AU - Sever, Matjaz

AU - Solano, Carlos

AU - Contentin, Nathalie

AU - de Wreede, Liesbeth C

AU - Czerw, Tomasz

AU - Hernandez-Boluda, Juan Carlos

AU - Hayden, Patrick

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

PY - 2021/7

Y1 - 2021/7

N2 - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.

AB - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.

KW - Busulfan

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Middle Aged

KW - Neoplasms

KW - Primary Myelofibrosis

KW - Retrospective Studies

KW - Thiotepa

KW - Transplantation Conditioning

KW - Vidarabine/analogs & derivatives

U2 - 10.1038/s41409-021-01222-z

DO - 10.1038/s41409-021-01222-z

M3 - SCORING: Journal article

C2 - 33526919

VL - 56

SP - 1593

EP - 1602

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -